Noven Sues To Block Mylan's Generic ADHD Patch
Noven Pharmaceuticals Inc. has filed patent infringement suits in two federal districts to stop Mylan Inc. from marketing a generic version of Daytrana, Noven's patch treatment for children with attention deficit...To view the full article, register now.
Already a subscriber? Click here to view full article